NEWS SEARCH ANALYSIS INSIGHT

360° SearchNetwork Hot Spots Trends

Advanced Search Options >>

Saturday, November 21, 2009 4:26 PM

Xarelto

Type: Keyphrase

Name: Xarelto

First Reported 11/20/2009 - Updated 11/20/2009 - 1 Documents

Bayer AG

Xarelto approval hopes revived?

Bayer HealthCare and have good news to present about their blood-thinner Xarelto--a potential blockbuster that the FDA declined to approve months ago. Results from a long-term clinical trial showed taking Xarelto led to an 82 percent lower risk that ... [FierceBiotech - 11/20/2009]

Entities: Xarelto, Bayer AG, Food and Drug Administration, Placebo

First Reported 21 hours ago - Updated 21 hours ago - 1 Documents

Results from study with Xarelto to be presented at ASH 2009

Findings from the phase III EINSTEIN-Extension study will be presented in the Late Breaking Abstract Session on 8th December 2009 at the 51st Annual Meeting of the American Society of Hematology () in New Orleans, Louisiana.The study investigated the ... [Pharmacy Europe - 21 hours ago]

Entities: Xarelto, American Society of Hematology, Anticoagulant, thromboembolism

First Reported 11/18/2009 - Updated 11/18/2009 - 1 Documents (in Health)

Bristol-Myers Squibb Company

Boehringer clot drug poses small bleed risk-study

The drug dabigatran raised major bleeding risk by less than 1 percent among patients with heart disease over a six-month period, a favorable result compared with bleeding risks of at least 2.5 percent seen in separate earlier studies of the lowest doses ... [Interactive Investor International - 11/18/2009]

Entities: Coagulation, Acute Coronary Syndrome, Heart Attack, Bristol-Myers Squibb Company

First Reported 11/03/2009 - Updated 11/03/2009 - 1 Documents

Johnson & Johnson

J&J chief calls job cuts 'difficult'

Two weeks after (NYSE:JNJ) , which tugged stocks downward, the world's biggest healthcare company is . Those cuts include 7,000 to 8,000 layoffs, mostly overseas.J&J chief executive (pictured) said in a statement, 'These types of changes are difficult ... [TheDeal.com - 11/03/2009]

Entities: Johnson & Johnson, Layoffs, Cougar Biotechnology Inc, Mentor Corporation, Xarelto

First Reported 11/04/2009 - Updated 11/04/2009 - 1 Documents

J&J to cut 8,000 jobs worldwide by 2011

will slash headcount by 6-7% – between 7,020 and 8,190 of its 117,000 employees worldwide – as part of a broad restructuring. The company declined to provide a more detailed breakdown of where the cuts might fall, saying only that the reductions are a ... [Medical Marketing And Media - 11/04/2009]

Entities: Johnson & Johnson, Goodrich Corporation, Xarelto, Fibrin, SIMPONI

First Reported 11/12/2009 - Updated 11/12/2009 - 1 Documents

Barclays PLC

STOCKS NEWS EUROPE-Bayer gains on Barclays, Merrill notes

Shares in Bayer AG (BAYGn.DE) gain 1.5 percent, making them one of the top gainers among German largecap stocks .GDAXI, afterBarclays initiates Bayer along with the European pharma sector with a 'equal weight' rating and BofA Merrill Lynch adds healthcare ... [Reuters UK - 11/12/2009]

Entities: Bayer AG, Barclays PLC, Merrill Lynch & Co Inc, Xarelto, Agrochemicals

First Reported 10/16/2009 - Updated 10/16/2009 - 2 Documents (in Health)

Reportlinker Adds The Canadian Pharmaceutical Market Outlook to 2013: Policy Environment, Market Structure, Pipeline Analysis, Growth Opportunities Re

http://www.reportlinker.com/p0115250/The-Canadian-Pharmaceutical-Market-Outlook-to-2013-Policy-environment-market-structure-pipeline-analysis-growth-opportunities.htmlThis report provides comprehensive coverage of the Canadian market, incorporating an ... [Yahoo! Canada - 10/16/2009]

Entities: Leading Brands Incorporated, Canada, Novopharm, Apotex, Xarelto

First Reported 07/14/2009 - Updated 07/14/2009 - 1 Documents (in Medicine)

REPEAT-UPDATE 1-Bayer, J&J to submit Xarelto data in Q4 earliest

* Data filing might take until early 2010- Bayer* FDA has asked for European market surveillance data* FDA also requested more data on completed, ongoing studies (Adds details, background)FRANKFURT, July 14 (Reuters) - Bayer (BAYG.DE) and Johnson & Johnson ... [Reuters - 07/14/2009]

Entities: Xarelto, Bayer AG, Food and Drug Administration

First Reported 08/30/2009 - Updated 08/30/2009 - 1 Documents (in Health)

New drug to replace "rat poison" warfarin

Patients at risk of stroke due to an irregular heartbeat should soon have a viable alternative to 50-year-old warfarin, after a new pill from Boehringer Ingelheim beat expectations in a major clinical study.The strong showing for the unlisted German company's ... [ONE News - 08/30/2009]

Entities: warfarin, Poison, Anticoagulant, Xarelto

First Reported 10/12/2009 - Updated 10/12/2009 - 1 Documents (in Health)

Johnson & Johnson earnings preview

(NYSE:JNJ), the world's biggest healthcare company that's been squeezed by generic competition, reports third-quarter earnings Tuesday morning. Alex Gorsky, worldwide chairman of medical devices and diagnostics; Dominic Caruso, vice president of finance ... [TheDeal.com - 10/12/2009]

Entities: Johnson & Johnson, New York Stock Exchange, Medical Devices, Chaumont (France)

Quotes

...Nicole Farmer, Bayer's British head of oncology, said: "We believed we had satisfied NICE's criteria for how Nexavar would be assessed -- however, the goal posts appeared to have moved. 'We shall appeal against the decision and if we are successful, this will enable the NHS to offer a similar level of access to Nexavar as other EU countries such as France, Germany, Spain, Italy and Romania where it has already been granted funding.' Nexavar is one of Bayer's top new drug hopes, along with anti-blood clotting pill Xarelto. It has proved successful against liver and kidney cancer and Bayer is also pursuing approvals for use against lung and breast tumours. Bayer believes it can generate peak worldwide sales of 2 billion euros ($2.99 billion) a year from the drug. LONDON, Nov 19 (Reuters) - Britain's health watchdog has blocked a critical liver cancercancer drug, saying it is too pricey for the state health service, leaving manufacturer Bayer vowing to appeal the decision."

UK's NICE says Bayer liver cancer drug too costly [Interactive Investor International - 11/19/2009]

...Dabigatran works instead by directly blocking a protein called thrombin that plays a major role in the clotting process. "There was less than a 1 percent increase in major bleeding with the highest doses of dabigatran" used in the study -- 110 milligrams and 150 mg -- Oldgren said in an interview at the annual scientific sessions of the American Heart Association in...

Boehringer clot drug poses small bleed risk-study [Interactive Investor International - 11/18/2009]

...Bayer along with the European pharma sector with a 'equal weight' rating and BofA Merrill Lynch adds healthcare to its most preferred list. "The medium-term growth outlook for Bayer, largely unaffected by patent expiration and U S healthcare reforms, looks relatively attractive once investors adjust to the likelihood that key pipeline drug Xarelto is going to be a commercial failure in strokes" BofA Merrill Lynch says in a note to clients

STOCKS NEWS EUROPE-Bayer gains on Barclays, Merrill notes [Reuters UK - 11/12/2009]

...4 billion and 1.7 billion a year starting in 2011, which "will provide additional resources to invest in new growth platforms." It also confirmed its earnings guidance for 2009 of $4.54 to $4...

J&J chief calls job cuts 'difficult' [TheDeal.com - 11/03/2009]

More Content

sort by: Date \| Relevance
Results from study with Xarelto to be presented... [Pharmacy Europe - 21 hours ago]
Xarelto approval hopes revived? [FierceBiotech - 11/20/2009]
UK's NICE says Bayer liver cancer drug too costly [Interactive Investor International - 11/19/2009]
Boehringer clot drug poses small bleed risk-study [Interactive Investor International - 11/18/2009]
STOCKS NEWS EUROPE-Bayer gains on Barclays, Mer... [Reuters UK - 11/12/2009]
Blopress [Irish Medical Times - 11/07/2009]
Blopress Plus [Irish Medical Times - 11/07/2009]
Clopidogrel HCS [Irish Medical Times - 11/07/2009]
Instanyl [Irish Medical Times - 11/07/2009]
Nplate [Irish Medical Times - 11/07/2009]
Ondansetron [Irish Medical Times - 11/07/2009]
Profal [Irish Medical Times - 11/07/2009]
Victoza [Irish Medical Times - 11/07/2009]
Denzapine tablets (50mg & 200mg) & Denz... [Irish Medical Times - 11/07/2009]
Monotrim 100mg & 200mg [Irish Medical Times - 11/07/2009]
Salofalk Rectal Foam [Irish Medical Times - 11/07/2009]
Estraderm TTS Discontinued [Irish Medical Times - 11/07/2009]
Trinordiol Discontinued [Irish Medical Times - 11/07/2009]
Xylocaine 4% w/v Topical Mucosal Solution in Sh... [Irish Medical Times - 11/07/2009]
J&J to cut 8,000 jobs worldwide by 2011 [Medical Marketing And Media - 11/04/2009]
J&J chief calls job cuts 'difficult' [TheDeal.com - 11/03/2009]
New hope on finding better blood thinners [The ... [Pharmacy Choice - 10/20/2009]
New hope on finding better blood thinners [Philadelphia Inquirer - 10/20/2009]
Reportlinker Adds The Canadian Pharmaceutical M... [Yahoo! Canada - 10/16/2009]
Reportlinker Adds The Canadian Pharmaceutical M... [Yahoo! Canada - 10/16/2009]
Hemophiliacs Appeal Ruling That Prevents Them S... [BNET - 10/14/2009]
Johnson & Johnson earnings preview [TheDeal.com - 10/12/2009]
New drug to replace "rat poison" warf... [ONE News - 08/30/2009]
REPEAT-UPDATE 1-Bayer, J&J to submit Xarelt... [Reuters - 07/14/2009]
US FDA Advisory Committee supports Bayer's NDA ... [PharmaBiz - 03/21/2009]

Blogs

sort by: Date \| Relevance
Bayer Launches New Anti-Clotting Drug in China [Biotech Sector and Stocks Analysis from Seeking ... - 07/05/2009] ChinaBio Today submits: Bayer Healthcare (BAYRY.PK) has launched its new anti-clotting drug Xarelto (rivaroxaban) in China following SFDA approval. As Liam Condon, ...
FDA, Clinical Trial Updates: JNJ, INCY, MEDX, C... [Healthcare Sector and Stocks Analysis from Seek ... - 05/30/2009] Mike Havrilla submits:Below is a summary of updates to the BioMedReports.com database of over 200 entries included in the FDA and Clinical Trial Calendars. The FDA ...
FDA Isn’t Ready to Approve J&J Anticlotting... [WSJ.com: Health Blog - 05/28/2009] Despite a 15-2 vote by an advisory panel in favor of the experimental anticlotting drug rivaroxaban, the FDA isn’t approving the drug at this point. Johnson & Johnson, ...
Analysts Like J&J’s Deal for Cougar [WSJ.com: Health Blog - 05/22/2009] Johnson & Johnson said late yesterday that it’s buying Cougar Biotechnology for about $894 million, or $43 a share. That’s a 16% premium to where the stock closed ...

Change Password

Log in to Silobreaker

Advanced Search Options

Xarelto